Rare and orphan diseases
Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets. To learn more about how Sciensus can facilitate and support your Europan expansion, visit: Rare Diseases and Orphan Drugs
Thought Leadership
Commercialization of rare & orphan products in Switzerland and smaller EU Markets
Thought Leadership
Expand into Europe: unlocking the orphan drug market
Blogs
Rare disease day 2025
Thought Leadership
Beyond compliance: unlocking the strategic potential of PASS in rare disease therapy
Events
World Orphan Drug Congress USA 2025
Blogs
The developing role of gene therapy in finding solutions to rare diseases
Blogs
Strategic timing: When should biotech firms consider launching expanded access programs?
Blogs
How to set up an EAP without a European presence
Blogs
Market access for orphan drugs in Switzerland: a guide for Biotechs